Urolithin A for Increased Energy Production
Biomarkers of mitochondrial function improve; subjective energy gains are less clear.
Overview
Verdict
How It Works
Dosing & Protocol
Typical dose
- Recommended dose
- 500-1,000 mg/day of urolithin A with food; mitochondrial biomarkers changed but subjective energy did not
- Expected timeframe
- 4 months
Protocol
- form
- Synthesised urolithin A such as Mitopure; pomegranate-derived products are unreliable given variable gut conversion
- duration
- 4 months
- co factor
- Take with food. Evidence is mixed and the distinction between cellular energy and felt energy matters here. Urolithin A trials show genuine changes in mitochondrial biology: plasma acylcarnitine profiles shift, skeletal muscle mitochondrial gene expression increases, and muscle endurance improves in randomised trials. What no trial has shown is improved subjective energy, reduced fatigue ratings or increased vitality - these have not been primary endpoints and where measured have not clearly separated from placebo. ATP production at the cellular level and the experience of having energy are only loosely related, and fatigue is driven far more by sleep, mood, anaemia and thyroid status.
- titration
- Up to 1,000 mg/day, as used in trials
- starting dose
- 500 mg/day with food
Evidence
What the studies say
No studies are yet linked to both Urolithin A and Increased Energy Production.
Safety
Caveats
Felt energy and cellular energy production are different things, and supplements marketed for mitochondrial energy routinely conflate them. Persistent fatigue deserves proper investigation rather than mitochondrial supplementation: iron deficiency anaemia, thyroid disease, sleep apnoea, diabetes, depression, coeliac disease, chronic kidney disease and medication effects are all common, treatable and identified with basic testing. Sleep quantity and quality, and physical activity, do more for daytime energy than any supplement. Safety of urolithin A: well tolerated at 500-1,000 mg/day over 4 months in trials, with no significant adverse effects reported and FDA GRAS status granted, but there is no established upper limit and no long-term data beyond about a year. Mild gastrointestinal upset is occasionally reported. Interactions have not been systematically studied, so caution is reasonable with any regular medication. Safety in pregnancy and breastfeeding is not established. Note that nearly all trials are funded by the ingredient developer. New, severe or progressive fatigue, particularly with weight loss, breathlessness or fever, needs medical assessment.
Less likely to help if
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.
Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.